DRI HEALTHCARE TRUST (DHT-U.CA) Fundamental Analysis & Valuation

TSX:DHT-U • CA23344H1091

11.68 USD
-0.77 (-6.18%)
Last: Mar 3, 2026, 07:00 PM
Overview Stock Chart Technical Analysis News

This DHT-U.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

4

Overall DHT-U gets a fundamental rating of 4 out of 10. We evaluated DHT-U against 34 industry peers in the Pharmaceuticals industry. There are concerns on the financial health of DHT-U while its profitability can be described as average. DHT-U has a correct valuation and a medium growth rate.


Dividend Valuation Growth Profitability Health

4

1. DHT-U.CA Profitability Analysis

1.1 Basic Checks

  • DHT-U had negative earnings in the past year.
  • DHT-U had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: DHT-U reported negative net income in multiple years.
  • In the past 5 years DHT-U always reported a positive cash flow from operatings.
DHT-U.CA Yearly Net Income VS EBIT VS OCF VS FCFDHT-U.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 0 50M -50M 100M

1.2 Ratios

  • DHT-U has a Return On Assets of -5.35%. This is comparable to the rest of the industry: DHT-U outperforms 58.82% of its industry peers.
  • Looking at the Return On Equity, with a value of -11.51%, DHT-U is in the better half of the industry, outperforming 64.71% of the companies in the same industry.
  • DHT-U has a better Return On Invested Capital (4.25%) than 73.53% of its industry peers.
  • DHT-U had an Average Return On Invested Capital over the past 3 years of 2.87%. This is significantly below the industry average of 8.22%.
  • The 3 year average ROIC (2.87%) for DHT-U is below the current ROIC(4.25%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA -5.35%
ROE -11.51%
ROIC 4.25%
ROA(3y)1.76%
ROA(5y)2.41%
ROE(3y)1.4%
ROE(5y)2.6%
ROIC(3y)2.87%
ROIC(5y)2.78%
DHT-U.CA Yearly ROA, ROE, ROICDHT-U.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 0 5 -5 10 -10 15

1.3 Margins

  • With an excellent Operating Margin value of 26.77%, DHT-U belongs to the best of the industry, outperforming 91.18% of the companies in the same industry.
  • In the last couple of years the Operating Margin of DHT-U has grown nicely.
  • The Profit Margin and Gross Margin are not available for DHT-U so they could not be analyzed.
Industry RankSector Rank
OM 26.77%
PM (TTM) N/A
GM N/A
OM growth 3Y23.29%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DHT-U.CA Yearly Profit, Operating, Gross MarginsDHT-U.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025 0 20 -20 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. DHT-U.CA Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so DHT-U is destroying value.
  • Compared to 1 year ago, DHT-U has less shares outstanding
  • Compared to 1 year ago, DHT-U has a worse debt to assets ratio.
DHT-U.CA Yearly Shares OutstandingDHT-U.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
DHT-U.CA Yearly Total Debt VS Total AssetsDHT-U.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • Based on the Altman-Z score of 1.02, we must say that DHT-U is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of 1.02, DHT-U is in the better half of the industry, outperforming 73.53% of the companies in the same industry.
  • DHT-U has a debt to FCF ratio of 4.43. This is a neutral value as DHT-U would need 4.43 years to pay back of all of its debts.
  • The Debt to FCF ratio of DHT-U (4.43) is better than 79.41% of its industry peers.
  • DHT-U has a Debt/Equity ratio of 0.95. This is a neutral value indicating DHT-U is somewhat dependend on debt financing.
  • With a Debt to Equity ratio value of 0.95, DHT-U is not doing good in the industry: 73.53% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 4.43
Altman-Z 1.02
ROIC/WACC0.52
WACC8.15%
DHT-U.CA Yearly LT Debt VS Equity VS FCFDHT-U.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 100M 200M 300M 400M

2.3 Liquidity

  • DHT-U has a Current Ratio of 1.19. This is a normal value and indicates that DHT-U is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of DHT-U (1.19) is worse than 70.59% of its industry peers.
  • DHT-U has a Quick Ratio of 1.19. This is a normal value and indicates that DHT-U is financially healthy and should not expect problems in meeting its short term obligations.
  • DHT-U has a Quick ratio (1.19) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.19
Quick Ratio 1.19
DHT-U.CA Yearly Current Assets VS Current LiabilitesDHT-U.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. DHT-U.CA Growth Analysis

3.1 Past

  • DHT-U shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -1601.87%.
  • The Revenue has been growing slightly by 2.28% in the past year.
  • Measured over the past years, DHT-U shows a very strong growth in Revenue. The Revenue has been growing by 29.36% on average per year.
EPS 1Y (TTM)-1601.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.89%
Revenue 1Y (TTM)2.28%
Revenue growth 3Y29.36%
Revenue growth 5YN/A
Sales Q2Q%-7.5%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.73% on average over the next years. This is quite good.
  • DHT-U is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.98% yearly.
EPS Next Y10.46%
EPS Next 2Y13.64%
EPS Next 3Y28.95%
EPS Next 5Y18.73%
Revenue Next Year0.61%
Revenue Next 2Y3.06%
Revenue Next 3Y18.42%
Revenue Next 5Y12.98%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DHT-U.CA Yearly Revenue VS EstimatesDHT-U.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
DHT-U.CA Yearly EPS VS EstimatesDHT-U.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1 2 3 4

More info and screens

Find the best growth stocksShow best growing peers

6

4. DHT-U.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for DHT-U. In the last year negative earnings were reported.
  • A Price/Forward Earnings ratio of 5.10 indicates a rather cheap valuation of DHT-U.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of DHT-U indicates a rather cheap valuation: DHT-U is cheaper than 94.12% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of DHT-U to the average of the S&P500 Index (24.27), we can say DHT-U is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 5.1
DHT-U.CA Price Earnings VS Forward Price EarningsDHT-U.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, DHT-U is valued a bit cheaper than the industry average as 79.41% of the companies are valued more expensively.
  • 88.24% of the companies in the same industry are more expensive than DHT-U, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 5.9
EV/EBITDA 7.1
DHT-U.CA Per share dataDHT-U.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • A more expensive valuation may be justified as DHT-U's earnings are expected to grow with 28.95% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.64%
EPS Next 3Y28.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

5

5. DHT-U.CA Dividend Analysis

5.1 Amount

  • DHT-U has a Yearly Dividend Yield of 4.57%, which is a nice return.
  • DHT-U's Dividend Yield is rather good when compared to the industry average which is at 0.37. DHT-U pays more dividend than 100.00% of the companies in the same industry.
  • DHT-U's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 4.57%

5.2 History

  • DHT-U has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
DHT-U.CA Yearly Dividends per shareDHT-U.CA Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

DPN/A
EPS Next 2Y13.64%
EPS Next 3Y28.95%
DHT-U.CA Yearly Income VS Free CF VS DividendDHT-U.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2021 2022 2023 2024 2025 0 50M -50M 100M

More info and screens

Find the best dividend stocksShow peers with best dividend

DHT-U.CA Fundamentals: All Metrics, Ratios and Statistics

DRI HEALTHCARE TRUST

TSX:DHT-U (3/3/2026, 7:00:00 PM)

11.68

-0.77 (-6.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)03-03
Earnings (Next)05-11
Inst Owners51.66%
Inst Owner ChangeN/A
Ins Owners0.97%
Ins Owner ChangeN/A
Market Cap642.52M
Revenue(TTM)188.92M
Net Income(TTM)-50.47M
Analysts80
Price Target16.09 (37.76%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 4.57%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)7.91%
Min Revenue beat(2)6.93%
Max Revenue beat(2)8.88%
Revenue beat(4)2
Avg Revenue beat(4)3.7%
Min Revenue beat(4)-0.64%
Max Revenue beat(4)8.88%
Revenue beat(8)5
Avg Revenue beat(8)10.36%
Revenue beat(12)9
Avg Revenue beat(12)21.51%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)3.45%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.22%
EPS NY rev (1m)-0.22%
EPS NY rev (3m)-0.58%
Revenue NQ rev (1m)2.75%
Revenue NQ rev (3m)0.03%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 5.1
P/S 3.4
P/FCF 5.9
P/OCF 5.84
P/B 1.46
P/tB N/A
EV/EBITDA 7.1
EPS(TTM)-0.91
EYN/A
EPS(NY)2.29
Fwd EY19.6%
FCF(TTM)1.98
FCFY16.96%
OCF(TTM)2
OCFY17.11%
SpS3.43
BVpS7.97
TBVpS-6.17
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.35%
ROE -11.51%
ROCE 5.91%
ROIC 4.25%
ROICexc 4.47%
ROICexgc 100.55%
OM 26.77%
PM (TTM) N/A
GM N/A
FCFM 57.68%
ROA(3y)1.76%
ROA(5y)2.41%
ROE(3y)1.4%
ROE(5y)2.6%
ROIC(3y)2.87%
ROIC(5y)2.78%
ROICexc(3y)3.05%
ROICexc(5y)3.04%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)3.99%
ROCE(5y)3.9%
ROICexgc growth 3Y91.89%
ROICexgc growth 5YN/A
ROICexc growth 3Y42.55%
ROICexc growth 5YN/A
OM growth 3Y23.29%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity 0.95
Debt/FCF 4.43
Debt/EBITDA 2.73
Cap/Depr 0.97%
Cap/Sales 0.52%
Interest Coverage 250
Cash Conversion 72.08%
Profit Quality N/A
Current Ratio 1.19
Quick Ratio 1.19
Altman-Z 1.02
F-Score3
WACC8.15%
ROIC/WACC0.52
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1601.87%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.89%
EPS Next Y10.46%
EPS Next 2Y13.64%
EPS Next 3Y28.95%
EPS Next 5Y18.73%
Revenue 1Y (TTM)2.28%
Revenue growth 3Y29.36%
Revenue growth 5YN/A
Sales Q2Q%-7.5%
Revenue Next Year0.61%
Revenue Next 2Y3.06%
Revenue Next 3Y18.42%
Revenue Next 5Y12.98%
EBIT growth 1Y16.2%
EBIT growth 3Y59.49%
EBIT growth 5YN/A
EBIT Next Year140.54%
EBIT Next 3Y57.03%
EBIT Next 5Y34.01%
FCF growth 1Y-4.36%
FCF growth 3Y12.04%
FCF growth 5YN/A
OCF growth 1Y-3.49%
OCF growth 3Y12.38%
OCF growth 5YN/A

DRI HEALTHCARE TRUST / DHT-U.CA FAQ

What is the fundamental rating for DHT-U stock?

ChartMill assigns a fundamental rating of 4 / 10 to DHT-U.CA.


What is the valuation status of DRI HEALTHCARE TRUST (DHT-U.CA) stock?

ChartMill assigns a valuation rating of 6 / 10 to DRI HEALTHCARE TRUST (DHT-U.CA). This can be considered as Fairly Valued.


Can you provide the profitability details for DRI HEALTHCARE TRUST?

DRI HEALTHCARE TRUST (DHT-U.CA) has a profitability rating of 4 / 10.